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Abstract 
Oxidative stress has been consistently linked to ageing-related neurodegenerative diseases 
leading to the generation of lipid peroxides, carbonyl proteins and oxidative DNA damage 
in tissue samples from affected brains. Studies from mouse models that express disease-
specific mutant proteins associated to the major neurodegenerative processes have 
underscored a critical role of mitochondria in the pathogenesis of these diseases. There is 
strong evidence that mitochondrial dysfunction is an early event on neurodegeneration. 
Mitochondria are the main cellular source of ROS and key regulators of cell death. 
Moreover, mitochondria are highly dynamic organelles that divide, fuse and move along 
axons and dendrites to supply cellular energetic demands, and therefore, impairment of any 
of these processes would directly impact on neuronal viability. Most of the disease-specific 
pathogenic mutant proteins have been shown to target mitochondria promoting oxidative 
stress and the mitochondrial apoptotic pathway. In addition, disease-specific mutant 
proteins may also impair mitochondrial dynamics and recycling of damaged mitochondria 
via autophagy. Thus, all these data suggest that ROS-mediated defective mitochondria may 
accumulate during and contribute to disease progression, indicating that strategies aimed to 
improve mitochondrial function or ROS scavenging may be of potential clinical relevance.  
 
Key words: Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, 
Huntington’s disease, oxidative stress, mitochondria, autophagy, mitochondrial dynamics. 
 3 
1. INTRODUCTION 
Neurodegenerative diseases are hereditary or sporadic conditions characterized by 
progressive atrophy and dysfunction of anatomically or physiologically related neurologic 
systems. Huge efforts are being made to develop therapies that counteract these devastating 
disorders, which encompass Alzheimer’s disease (AD), Parkinson’s disease (PD), 
amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD). However, until now 
none of the strategies tested have been proved successful, mainly due to our incomplete 
understanding of the pathogenesis of these ageing-related disorders. Despite their 
heterogeneity, these diseases share common features such as formation of insoluble 
disease-specific protein aggregates and oxidative stress that ultimately result in neuronal 
death. Therefore, it is conceivable to speculate the existence of a unifying etiological factor. 
Among all the initial cellular derangements, mitochondrial dysfunction seems to play a 
pivotal role [1, 2]. Mitochondria are the main cellular source of reactive oxygen species 
(ROS) and have been described as key regulators of cell survival and death [3-5]. 
Mitochondrial metabolism decline and mitochondrial oxidative stress have been directly 
implicated in ageing [6, 7], arising as a risk factor for the sporadic forms of the 
neurodegenerative diseases. Moreover, different studies have shown that most of the 
disease-specific proteins are able to interact with the organelle resulting in mitochondrial 
failure and ROS production [8-10]. However, despite evidence of abnormalities in 
mitochondrial localization, structure and function in samples from symptomatic patients, it 
is still largely debated whether mitochondrial impairment and enhanced oxidative stress are 
causal or merely a consequence of the neurodegenerative processes. Recently, studies from 
genetically-modified mice have proved useful to unravel the contribution of mitochondria 
as a major pathogenic factor leading to brain neurodegeneration. This review will focus on 
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some of these relevant new insights, lending further support for the involvement of 
oxidative stress and altered mitochondrial function in neurodegenerative diseases. Clearly, 
uncontrolled generation of ROS would be expected to affect different cells and hence the 
course of progression of multiple pathologies linked to neurodegeneration, such as obesity, 
insulin sensitivity, cardiovascular and liver diseases, which have been covered in recent 
reviews [11-13]. 
2. MITOCHONDRIAL CONTROL OF OXIDATIVE STRESS. 
Mitochondria provide more than 90 percent of the cellular ATP requirement, and hence can 
be considered the powerhouse of cells. Maintenance of mitochondrial function is 
particularly important in neurons given that they rely on glucose oxidation for energy 
production [14]. Moreover, neurons are highly specialized cells whose major function is 
intercommunication. This interactive activity requires tightly regulated signalling systems, 
mainly in the synaptic compartments, that rely on the correct function of ATP-dependent 
processes such as ion channels, receptors, pumps, vesicle release, and neurotransmitters 
recycling [14].  The ability of mitochondria to divide, fuse, and migrate will facilitate the 
transmission of energy across long distances and will help neurons to meet the high-energy 
demands, especially on synapses. In addition to its well-known role on meeting 
bioenergetic demands, mitochondria display other important cellular functions including 
regulation of Ca2+ homeostasis [2], ROS signalling [4] and apoptosis [3, 5]. Derangements 
in any of these intimately interrelated mitochondrial functions result in oxidative stress, 
perturbed Ca2+ signaling, and ultimately cell death, underscoring the crucial role of 
mitochondria in cell fate decisions. Therefore, in this section we will briefly describe the 
role of mitochondria in ROS generation, Ca2+ homeostasis and cell death regulation. 
2.1. Mitochondria and ROS generation 
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Mitochondria are the major endogenous source of ROS, which are generated mainly as by-
products of the oxidative phosphorylation [15] (Fig. 1). When produced in an uncontrolled 
fashion, mitochondrial-derived ROS may compromise mitochondrial function and cell 
survival [5]. Indeed, in the course of normal physiological respiration it is estimated that up 
to 2-4 % of the O2 consumed by mitochondria is converted into superoxide radicals (O2.-), 
although recent determinations have reduced this figure to about 0.1-0.5% [16]. O2.- 
generation is stimulated by high mitochondrial membrane potential (∆Ψm) [17], whereas a 
mild uncoupling activity mediated by uncoupling proteins (UCPs) results in up to 70% drop 
in ROS generation. [18]. Moreover, UCP2 overexpression in brain mitochondria has been 
shown to be cytoprotective in several models of ischemic injury [19].  
In addition to the respiratory chain, several mitochondrial flavoenzymes have been shown 
to produce ROS with appreciable rates as shown with either isolated enzymes or 
mitochondria, although their specific contribution under physiological conditions to ROS 
generation and cell regulation is unknown. Especially relevant in brain are monoamine 
oxidases (MAOs) located in the outer membrane that catalyze oxidation of biogenic amines 
accompanied by release of hydrogen peroxide (H2O2) [20] (Fig. 1). Some authors suggested 
that an upregulation of MAO-B and the resulting ROS production might be responsible for 
the mitochondrial damage in PD [21, 22]. Elevated MAO-B activity in brain tissue as well 
as in platelets has been also found in other neurodegenerative diseases, including AD [23, 
24]. Indeed, MAO-B inhibitors (L-deprenyl and rasagiline) have been shown to be effective 
in treating PD and possibly AD, with concomitant extension of life span, although its 
neuroprotective effect may involve actions other than the inhibition of the enzyme, 
including anti-apoptotic activities and induction of antioxidant enzyme expression [25]. 
Intriguingly, recent data from a double blind trial in PD patients, showed that low (1 mg per 
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day) but not high (2 mg per day) rasagiline displayed disease-modifying effects [26]. Other 
well-established source of ROS is the flavin-containing enzyme dihydrolipoyl 
dehydrogenase within the α-ketoglutarate dehydrogenase complex (KGDHC) [27-29] (Fig. 
1). KGDHC is tightly associated with the matrix side of the inner membrane and catalyzes 
oxidation of α-ketoglutarate to succinyl-CoA using NAD+ as electron acceptor. Low 
availability of NAD+ stimulates ROS generation, whereas the physiological catalytic 
activity of the enzyme is inhibited [28]. Therefore, any condition that restricts the re-
oxidation of NADH in the respiratory chain increases the intramitochondrial NADH/NAD+ 
ratio, hence promoting KGDHC-mediated ROS production.  KGDHC is also sensitive to 
oxidative stress [29] and the enzyme activity is substantially reduced in postmortem brain 
samples from AD and PD patients [30, 31]. Moreover, recent studies in AD transgenic 
mouse models show that KGDHC impairment accelerates amyloid pathology and memory 
deficits through increased mitochondrial oxidative stress [32]. 
Specific ROS can be stimulated by nitrogen species [33, 34] (Fig. 1). Nitric oxide (NO) is 
produced by nitric oxide synthases (NOSs), a family of enzymes that catalyze the NADPH-
dependent oxidation of L-arginine to yield L-citrulline and NO. Moreover, the generation 
of O2.- and NO in close spatial proximity can give rise to the potent oxidant peroxynitrite. 
The first reports of a mitochondrial NOS isoform (mtNOS) were from Bates et al., who 
demonstrated the presence of NOS in nonsynaptosomal rat brain and liver mitochondria 
[35]. However, although the existence of mtNOS has been described in the last decade in 
mitochondrial fractions isolated from different sources, recent evidence in ultrapurified rat 
liver mitochondria has questioned its existence (at least in rat liver) and hence the in situ 
generation of NO and the consequent generation of peroxynitrite within mitochondria [36]. 
NO might affect respiratory chain activity in different ways. Reversible inhibition of 
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mitochondrial respiration can result from the interaction of NO with cytochrome c oxidase, 
i.e., by S-nitrosation of key cysteine residues of complex IV [33]. In fact, NO has been 
identified as a physiological regulator of electron transfer and ATP synthesis. The 
inhibition of cytochrome c oxidase not only affects O2 consumption, but also impacts on 
the redox status of the respiratory chain and thus on O2.- generation. Further, NO and 
peroxynitrite can also cause S-nitrosation of complex I resulting in reversibly increased 
ROS production [34].  
Although low levels of ROS are important for many cellular metabolic processes through 
activation of different enzymatic cascades and several transcriptional factors [4], an 
imbalance that favors the production of ROS over its removal will irremediably result in 
oxidative stress. 
2.2. Mitochondria as a target of ROS. 
Mitochondria are not only an important source of ROS generation in aerobic cells, but they 
are also sensitive targets for the damaging effects of oxygen radicals [5]. The accumulation 
of specific oxidant species within mitochondria can oxidize a broad range of bio-molecules, 
including lipids, proteins and nucleic acids, which can extensively impair mitochondrial 
function resulting in further enhancement of ROS production and cell death. For instance, 
damage of mitochondrial DNA (mtDNA), which is especially susceptible to attack by ROS 
owing to its close proximity to the electron transport chain and the lack of protective 
histones, not only can compromise the provision of energy to satisfy the cellular demands 
but also can result in enhanced ROS generation through the loss of functional respiratory 
complexes [7].  
Membrane lipids and proteins are also critical targets for oxidative damage. The 
inactivation of mitochondrial iron-sulfur (Fe-S) proteins, in particular aconitase, may have 
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major consequences. First, the formation of an inactive [3Fe-4S]+ cluster results in the 
simultaneous release of Fe2+ and H2O2 that stimulates hydroxyl radical generation via 
Haber-Weiss and Fenton reactions [37]. Administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a model of PD in mice, has been shown to mobilize an early 
mitochondrial pool of iron concomitant to aconitase inactivation, an effect that is 
significantly attenuated in transgenic mice overexpressing MnSOD [38].  Inhibition of 
mitochondrial aconitase could also result in Krebs cycle impairment and hence energy 
production. Moreover, aconitase is associated with protein-mtDNA complexes called 
nucleoids. In this context, aconitase stabilizes mtDNA and therefore, the reversible 
modulation of the nucleoids by aconitase inactivation may directly influence mitochondrial 
gene expression [39]. 
Lipid peroxidation has been reported to impair the barrier function of cellular membranes 
resulting in cell death [40]; an increase in mitochondrial lipid peroxides may contribute to 
reduce mitochondrial membrane potential and Ca2+ buffering capacity. Cardiolipin 
molecules are particularly susceptible to oxidation due to their high content of unsaturated 
fatty acids [41, 42]. Interestingly, compared to other tissues, brain cardiolipin displays 
differences in fatty acid composition that could render this phospholipid more susceptible 
to peroxidation [43]. Cardiolipin molecules are required for functional activity of a number 
of inner mitochondrial membrane proteins, including respiratory chain complexes and 
mitochondrial anion carriers such as the adenine nucleotide translocase (ANT). Thus, 
oxidative damage to cardiolipin may have deleterious effects in mitochondrial function. 
Additionally, recent studies have shown that peroxidation of cardiolipin may promote cell 
death induced by an apoptotic stimulus, by facilitating the detachment of cytochrome c 
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from the inner membrane [44, 45], restructuring of the biophysical properties of the bilayer 
[45] and promoting Ca2+-induced mitochondrial permeability transition (MPT) [46]. 
2.3. Mitochondrial defenses against oxidative stress.  
Mitochondria possess a wide network of antioxidant systems to eliminate ROS and repair 
oxidative damage generated during normal aerobic metabolism that include several 
enzymatic systems as well as water- and lipid-soluble antioxidants (e.g., coenzyme Q, 
vitamins C and E) (Fig. 2). Most important for mitochondrial antioxidant protection is the 
tripeptide glutathione (L-γ-glutamyl-L-cysteinylglycine, GSH) and the different GSH-
linked enzymatic defense systems [47]. Mitochondrial GSH arises from the transport of 
cytosol GSH into the mitochondrial matrix [48]. One of the highlights of this transport 
mechanism is its dependence on appropriate membrane dynamics; the loss of mitochondrial 
fluidity impairs the function of the mitochondrial carrier of GSH, resulting in its depletion 
[49, 50]. Cumulating evidence shows that oxidative cell death is caused by the specific 
depletion of this particular pool of GSH [45, 51-53]. GSH can act non-enzymatically by 
direct interaction with electrophiles, although this reaction is greatly enhanced in the 
presence of GSH-S-transferases. Among GSH-linked enzymes involved in maintaining 
mitochondrial redox homeostasis are selenium (Se)-dependent glutathione peroxidases 
(Gpx) 1 and 4 (Fig. 2). Gpx4 reduces hydroperoxide groups on phospholipids, lipoproteins, 
and cholesteryl esters and is considered to be the primary enzymatic defense against 
oxidative damage to cellular membranes [54]. The critical role of Gpx4 is underscored by 
the fact that whereas Gpx1-knockout mice are fully viable, disruption of the Gpx4 gene in 
the mouse results in embryonic lethality [55]. Other members of the family of 
mitochondrial GSH-linked redox enzymes are glutaredoxin 2 (Grx2), which catalyzes 
 10 
glutathione-dependent dithiol reaction mechanisms, reducing protein disulfides, monothiol 
reactions, and mixed disulfides between proteins and GSH [56, 57]. 
The mitochondrial thioredoxin system, which includes thioredoxin 2 (Trx2) and 
thioredoxin reductase 2 (TrxR2), is another potential source of disulfide reductase activity 
(Fig. 2). Trx2 is a multifunctional selenoprotein containing two redox-active cysteines in its 
conserved active site that form a dithiol group which catalyzes the reduction of disulfides 
[58]. Thioredoxins reduce protein disulfides at much higher rates than Grx [59]. The 
physiological significance of this system is emphasized by the finding that Trx2 deficiency 
is embryonic lethal [60]. The thioredoxin system can also interact with peroxiredoxins 
(Prx), which constitute a novel family of thiol-specific peroxidases that rely on Trx as the 
hydrogen donor for the reduction of H2O2 and lipid hydroperoxides [61].  
A key mechanism to control the production of ROS is through the transcriptional regulation 
of these enzymatic strategies. For instance, a number of transcription factors including 
nuclear respiratory factor 1/2 (Nrf1/2), along with PPARgamma coactivator 1α (PGC-1α) 
and forkhead box class O (FOXO) have been described to modulate the expression of 
antioxidant enzymes such as MnSOD, Prx3, and Trx2, protecting against oxidative stress in 
a number of conditions and cell types [62, 63]. PGC-1α null mice are much more sensitive 
to the neurodegenerative effects of MPTP and kainic acid, which affect the substantia nigra 
and hippocampus, respectively, in an oxidative stress-dependent fashion [62]; similarly, 
increased sensitivity to oxidant-mediated cell death has been seen in models of PD, HD and 
ALS due to the deletion of the Nrf2 gene [64-66]. Overall, these findings unravel novel 
neuroprotective pathways that confer resistance to a variety of stress-related 
neurodegenerative insults. 
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Intermediates of the mitochondrial respiratory chain can also contribute to the 
mitochondrial antioxidant defense. Ubiquinol (QH2) has been shown to act as a reducing 
agent in the elimination of various peroxides including lipid radicals and the regeneration 
of vitamin E from the α-tocopheroxyl radical [67]. Thus, coenzyme Q (CoQ10) acts a 
source of O2.- when partially reduced (semiquinone form) and as an antioxidant when fully 
reduced (ubiquinol). Besides its free radical scavenging activity, CoQ10 has been described 
to prevent apoptotic cell death by blocking Bax binding to mitochondria and by inhibiting 
activation of the MPT [68, 69]. Moreover, CoQ10 is a cofactor of mitochondrial UCPs and 
therefore, it may also be of benefit through reducing ROS generation via activation of these 
proteins. In several in vivo and in vitro models of neurodegenerative diseases 
administration of CoQ10 has been shown to exert neuroprotection [70-72], and based on 
these experimental data several clinical trials have been recently initiated to test its efficacy 
as a therapy for neurodegenerative disorders [73-75]. 
2.4. Ca2+ homeostasis, MPT and cell death.  
Mitochondria actively regulate cellular Ca2+ homeostasis. It is well known that the removal 
of Ca2+ from the cytoplasm results in mitochondrial accumulation in the matrix. Indeed, 
mitochondria are often located in close contact with the sources that contribute to the rise of 
cytosolic Ca2+, such as the endoplasmic reticulum (ER) and the plasma membrane. For 
instance, in excitotoxic neuronal cell death, overactivation of N-methyl-D-aspartate 
(NMDA) receptors induces cytosolic and mitochondrial rises in Ca2+ concentrations, 
underlying the relevance between cytosolic and mitochondria Ca2+ regulation in cell death 
[76]. The major metabolic effect of elevated mitochondrial Ca2+ is the upregulation of ATP 
production through activation of dehydrogenases of the TCA cycle as well as stimulation of 
the ATP synthase (complex V) and the ANT [77] (Fig. 1). Mitochondria also participate in 
 12 
shaping the space and temporal patterning of cytosolic Ca2+, contributing to many Ca2+-
mediated signalling processes [78]. Conversely, excessive Ca2+ uptake has been shown to 
induce MPT, which results in secondary burst of ROS [79] and the subsequent release of 
proapoptotic peptides such as cytochrome c that trigger apoptosis [80]; thus, illustrating the 
critical role of mitochondria in the excitotoxicity observed in different neurodegenerative 
diseases [2].  
Several lines of evidence suggest the existence of an intricate crosstalk between Ca2+ 
handling and mitochondrial ROS generation [81] (Fig. 1). Mitochondrial Ca2+ influx causes 
mild uncoupling of ∆Ψm, which should decrease ROS production; however, it has been 
shown to enhance its production when respiratory complexes are inhibited [82]. Stimulation 
of the TCA cycle and oxidative phosphorylation by Ca2+ may also enhance ROS output by 
stimulating electron flow and mitochondrial load work. Indeed, mitochondrial ROS 
generation correlates well with metabolic rate [83], suggesting that a faster metabolism 
results in more electron leakage. In addition, Ca2+-induced NO synthesis may increase ROS 
production by inhibiting complex IV, as previously mentioned. Furthermore, Ca2+ can 
promote cytochrome c dissociation from the mitochondrial inner membrane, either by 
competing for cardiolipin binding sites or by inducing the MPT [84, 85]. These events can 
result in blockage of respiratory chain at complex III, which in turn would stimulate O2.- 
generation. Recently, to illustrate the relevance of the ER-mitochondria cross talk in Ca2+-
mediated neurodegeneration, Sano et al. reported in monosialo gangliosides-1 (GM1) 
gangliosidosis, a neurological disorder characterized by β-galactosidase deficiency, the 
accumulation of GM1 at the mitochondrial associated ER membranes [86]. 
MPT has been shown to be promoted by thiol oxidation and inhibited by antioxidants, 
lending support for a role of ROS in pore opening [87].  The nature and composition of 
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MPT is still unclear, although several components have been described including the 
VDAC, the ANT and the soluble matrix protein cyclophilin D (CypD). In addition, the 
phosphate carrier has also been implicated in MPT because its depletion results in delayed 
cytochrome c mobilization and apoptosis [88]. The association of ANT and VDAC in 
contact sites between the inner and outer mitochondrial membrane forms a large 
conductance channel that, when opened, dissipates ∆Ψm and allows matrix solutes < 1.5 
kDa and Ca2+ to be released from the mitochondrial matrix. Pro-oxidant agents that target 
the MPT pore components have been shown to cause VDAC oxidation, protein thiol 
modifications in the ANT, and CypD recruitment to the inner membrane and binding to 
ANT, conditions that promote Ca2+-induced pore opening [89-91].  
The role of MPT in apoptosis is still under debate. For instance, recent experiments have 
shown a major role for MPT in ischemia-reperfusion injury but not in other forms of cell 
death such as developmental apoptosis. Mitochondria from CypD-deficient mice showed a 
general defect in the Ca2+-induced permeability transition, but had no developmental 
defects associated with a lack of apoptosis [92]. Mitochondrial outer membrane 
permeabilization induced by the pro-apoptotic protein Bid, Bax or by apoptotic stimuli was 
intact in CypD null mice. In contrast, cell death induced by ischemia–reperfusion injury in 
the heart or brain was defective in CypD-deficient mice. Moreover, although VDAC has 
been proposed as an integral component of MPT and in mitochondrial outer membrane 
permeabilization, recent data have discarded a role for VDAC in apoptosis. Murine cells 
deficient in all three VDAC isoforms successfully undergo intrinsic apoptosis [93]. 
Furthermore, the isoform VDAC2 has been described to be antiapoptotic [94]. Similarly, 
mitochondria from murine cells lacking ANT1 and ANT2 can still undergo Ca2+-induced 
swelling and MPT, although at a higher threshold, which has been considered as a sign 
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against a role for ANT in MPT and hence in mitochondrial outer membrane 
permeabilization [95]. However, the ability of ANT1/ANT2-deficient cells to undergo MPT 
might be due to the functional compensation by a novel ANT isoform identified recently 
[96], or by other mitochondrial carriers able to form pores in the inner membrane such as 
the ornithine/citrulline transporters or the phosphate carrier [88]. Thus, regardless of the 
ultimate phenotype of cell death, MPT plays a critical role in mitochondrial 
pathophysiology and hence its targeting can be of relevance in neurodegenerative diseases. 
3. PATHOGENESIS OF NEURODEGENERATIVE DISEASES: CONTRIBUTION 
OF OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION.  
The brain is especially susceptible to free radical damage. This vulnerability can be 
explained in part by its elevated metabolic rate, the high content of membrane 
polyunsaturated fatty acids susceptible to ROS-mediated peroxidation [97] and its relative 
low abundance of antioxidant defense compared with other organs.  
Oxidative stress has been consistently associated with neurodegenerative disorders. This 
tenet is mainly based on analyses of postmortem brain tissues from affected patients 
showing lipid peroxidation, elevated protein carbonyls content and presence of 8-hydroxy-
2’-deoxyguanosine, a marker of oxidative DNA damage [98-101]. In addition, reduced 
levels of antioxidants and higher content of lipid peroxides have been observed in aged 
compared with young brain tissues [102]. Similarly, many studies have shown that old 
mitochondria are morphologically altered and functionally less efficient relative to young 
ones contributing to more oxidants and less ATP generation [6, 7], indicating that the 
accumulation of oxidative damage during life span might influence the neuropathology of 
late-onset neurodegenerative diseases [102]. However, based on the correlative nature of 
these observations, it is difficult to distinguish whether oxidative stress is only a late sign of 
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brain injury and hence a consequence rather than a cause of the disease, questioning the 
contribution of oxidative stress as an etiological factor in neurodegenerative diseases. 
Recently, although the onset of most neurodegenerative diseases is sporadic (not inherited) 
and the genetic mutations discovered until now account for only a small fraction of early-
onset cases, the generation of genetically-modified mice that express these disease-causing 
mutations has emerged as an useful tool to underline the contribution of oxidative stress 
and the mitochondrial dysfunction in the pathogenesis of the main ageing-related 
neurodegenerative disorders. Some of these major breakthroughs will be briefly 
summarized in the following subsections.   
3.1. Alzheimer’s disease (AD)  
AD is a progressive neurodegenerative dementia associated with the extracellular presence 
of senile plaques composed of fibrillar amyloid-β peptide (Aβ), intracellular neurofibrillary 
tangles (NFT) of hyperphosphorylated tau, and selective synaptic and neuronal loss, mainly 
in brain regions related to memory and cognition such as entorhinal and frontal cortices and 
hippocampus [103]. Cumulating evidence suggests that increased Aβ levels, resulting from 
altered proteolytic processing of the amyloid precursor protein (APP) and reduced 
clearance of these neurotoxic forms, play a pivotal role in the pathogenesis of the disease 
[103, 104]. Among the mechanisms through which Aβ exerts its toxicity there is extensive 
literature supporting a role for oxidative stress [105-107]. Moreover, oxidative stress can 
further stimulate amyloidogenic processing and tau phosphorylation [108-110], initiating 
an auto-amplification loop that culminates in a toxic vicious cycle. Studies from AD 
transgenic mice show that oxidative damage precedes amyloid plaque deposition [106, 111] 
with alterations in mitochondrial proteome and function occurring even earlier [112-114].  
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Intracellular Aβ accumulates in brain mitochondria from AD transgenic mice and patients. 
It has been widely reported that Aβ interaction with mitochondria, results in ROS 
generation and mitochondrial dysfunction [115-117] (Fig. 3). Specifically, its interaction 
with Aβ-binding alcohol dehydrogenase (ABAD) results in ROS generation and 
mitochondrial dysfunction, and overexpression of ABAD in mutant APP transgenic mice 
has shown to exacerbate neuronal oxidative stress and spatial and temporal memory 
impairment [117, 118] (Fig. 3). Further support for the involvement of mitochondrial 
oxidative stress comes from a recent study of Dumont et al. where the partial genetic 
deletion of dihydrolipoyl succinyltransferase enzyme, a key subunit specific to the 
mitochondrial KGDHC, increases Aβ  plaque burden, nitrotyrosine levels and accelerates 
the occurrence of deficits in spatial learning and memory in a transgenic mouse model that 
carry the human APP with two mutations (Tg19959 mice) [32]. Aβ may also promote MPT 
by binding to CypD [119] (Fig. 3). CypD-deficient cortical mitochondria are resistant to 
Aβ- and Ca2+-induced mitochondrial swelling. Moreover, CypD deficiency substantially 
improves mitochondrial stress, alleviates Aβ-mediated reduction of long-term potentiation, 
and ameliorates behavioral and synaptic function in mutant APP transgenic mice [119]. 
Overall these studies underscore the relevance of mitochondria in Aβ neurotoxicity and 
suggest that the control over the mitochondrial oxidative state could determine AD 
pathogenesis. Indeed, hemizygous deficiency of the mitochondrial antioxidant enzyme 
MnSOD significantly increases brain Aβ levels and accelerates the onset of behavioral 
changes in AD transgenic mice [120, 121]. Conversely, MnSOD overexpression reduces 
oxidative stress and markedly attenuates the phenotype of Tg19959 mice [122]. In 
agreement with these studies, we have recently demonstrated that the mitochondrial pool of 
GSH rather than cytosol GSH determines Aβ susceptibility [51]. Reduced mitochondrial 
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GSH content can result from cholesterol-mediated perturbation of mitochondrial membrane 
dynamics [49, 50]. Using genetic mouse models of cholesterol loading such as sterol-
regulatory element-binding protein 2 (SREBP-2) transgenic mice and Niemann-Pick 
disease type C1 (NPC-1) knockout mice, we have shown that increased brain cholesterol 
selectively depletes mitochondrial GSH levels and exacerbates Aβ-induced 
neuroinflammation and neurotoxicity. In vivo, following a continuous 
intracerebroventricular delivery of human Aβ, we found that the SREBP-2 transgenic mice 
display increased oxidative damage, neuroinflammation, synaptic loss, and neuronal death 
with markers of apoptosis and oxidant-dependent cell death [51]. All these endpoints were 
reversed by treatment with GSH ethyl ester, a cell-permeable form of GSH, which 
significantly increased the pool of mitochondrial GSH in Tg-SREBP-2 mice. Thus, these 
findings define a novel role of cholesterol in AD pathogenesis, which has been previously 
identified as a major risk factor for the disease [123]. In addition to fostering Aβ generation 
by facilitating β- and γ-secretases cleavage of APP in lipid rafts [124-127], the trafficking 
of cholesterol to mitochondria specifically sensitizes neurons to Aβ-mediated cell death by 
depleting the mitochondrial pool of GSH. Interestingly, we observed enhanced 
mitochondrial cholesterol accumulation and mitochondrial GSH depletion in old APP/PS1 
transgenic mice after Aβ accumulation suggesting that Aβ might itself regulate cholesterol 
levels [51]. However, whether the alterations of mitochondrial GSH levels can modulate 
Aβ-induced memory impairment in these mice is unknown and will require further 
analysis. The regulatory role of Aβ on cholesterol homeostasis has been also reported in 
previous studies where both pathological presenilin mutations [128] and Aβ-induced 
membrane oxidative stress [129] results in increased amounts of cholesterol accompanied 
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with an altered sphingolipid metabolism. Elevated levels of ceramides and membrane 
cholesterol are found in vulnerable brain regions of AD patients with mild to moderate 
symptoms [129], suggesting that these abnormalities occur relatively early in the course of 
the disease. In vitro, Aβ has been shown to induce apoptosis via the 
sphingomyelin/ceramide pathway in various brain cells [130, 131]. Studies in cortical 
neurons report early increases in intracellular levels of the ceramide glycosylated derivative 
disialolactosylceramide (GD3) after Aβ challenge, describing a causal relationship among 
GD3 formation, cell-cycle activation, and neuronal death [132]. Recent observations further 
support a role for GD3 in promoting Aβ neurotoxicity, as the genetic downregulation of 
GD3 synthase, the enzyme responsible for the synthesis of GD3 from 
monosialolactosylceramide (GM3), reduces Aβ plaque load and improves memory in 
APP/PS1 transgenic mice [133]. Both ceramide and ganglioside GD3 has been shown to 
act directly on mitochondria and induce MPT with the release of cytochrome c [134, 135], 
however, the possibility that these sphingolipids contribute to Aβ-induced cell death by 
targeting the mitochondrial pathway has not been established yet and will required future 
work. 
Recent observations have described that memantine, an uncompetitive, moderate-affinity 
antagonist of NMDA receptors, exhibit disease-modifying effects in triple transgenic 
(3xTg-AD) mice, which harbor PS1M146V knockin alleles and APPSwe and tauP301L 
transgenes. Memantine restored cognition, reduced the levels of toxic Aβ species as well as 
the content of tau and hyperphosphorylated tau, and strikingly, prevented Aβ-induced 
inhibition of long-term potentiation (LPT) in the hippocampus of cognitively normal mice 
[136]. Whether these therapeutics effects of memantine were accompanied by the reversal 
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of mitochondrial Ca2+ rise, expected from the overactivation of NMDA, was not analyzed 
and deserves further investigation.  
3.2. Parkinson’s disease (PD) 
PD is characterized by the loss of dopaminergic (DA) neurons in the substantia nigra and 
the accumulation of intraneuronal proteinaceous inclusions, known as Lewy bodies. 
Pioneering evidence pointing to mitochondrial oxidative stress in PD came from studies 
where agents that cause Parkinsonism (MPTP, rotenone, 6-hydroxydopamine) inhibited 
complex I of the mitochondrial respiratory chain resulting in ROS production [137, 138]. 
Different reports showed that mice overexpressing antioxidant enzymes are protected 
against these parkinsonian agents [139-141] whereas mice deficient in Gpx, MnSOD or 
dihydrolipoyl dehydrogenase display increased vulnerability [142-144], emphasizing the 
concept that mitochondrial oxidative stress may play a major role in PD.  However, the 
relevance of these findings using neurotoxins is uncertain by the fact that they may have 
pleiotropic pharmacological effects in DA neurons, effects on non-DA neurons, and most 
importantly, the vast majority of patients are never exposed to these poisons.  
Another interesting approach was the generation of a conditional knockout mouse with 
disruption of the gene for mitochondrial transcription factor A (Tfam) in DA neurons. The 
knockout mice have reduced mtDNA expression and respiratory chain deficiency in 
midbrain DA neurons, which, in turn, leads to a parkinsonism phenotype with adult onset 
of slowly progressive impairment of motor function, thus providing experimental support 
for the hypothesis that acquired respiratory chain dysfunction may be of pathophysiological 
importance in PD [145]. 
However, although the concept that mitochondrial dysfunction as a potential contributory 
cause to PD pathogenesis has been launched about two decades ago, the most convincing 
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evidence came from the characterization of genes mutated in familial PD with putative 
functional roles within mitochondria. Several studies have suggested an association of 
many of the proteins linked to PD with the mitochondrion, including, α-synuclein, DJ-1 
(PARK7, Parkinson disease protein 7), parkin, PTEN induced putative kinase 1 (PINK1), 
and HtrA serine peptidase 2 (HtrA2/OMI) (Fig. 3). How these proteins regulate 
mitochondrial function is not fully clear, even though recent data indicate an intricate 
relationship between them [146-148] and their loss of function significantly affects 
mitochondria. For instance, PINK1 and parkin knockout mice both display impaired 
mitochondria and decreased antioxidant capacity specifically within nigrostriatal 
dopaminergic circuit [149-151]. Studies in PINK1 knockout mouse brain describe elevated 
susceptibility to H2O2 or heat-shock with decreased activities of the respiratory complexes 
as well as aconitase [149]. Parkin, but not its pathogenic mutants, stabilizes PINK1 by 
interfering with its degradation via the ubiquitin-mediated proteasomal pathway [152]. In 
addition, recent reports showed that PINK1 can regulate parkin function through direct 
phosphorylation [153]. The phosphorylation of parkin by PINK1 activates parkin E3 ligase 
function and enhances parkin-mediated ubiquitin signaling through the NF-κB pathway 
[153]. Parkin-mediated ubiquitin signaling is impaired by PD-linked pathogenic PINK1 
mutations [153]. PINK1 may also regulate calcium efflux from mitochondria via the 
mitochondrial Na+/Ca2+ exchanger and therefore, its deficiency causes mitochondrial 
calcium overload, resulting in ROS generation and MPT [154]. Moreover, disease-causing 
mutations in PINK1 have been reported to decrease HtrA2 phosphorylation affecting its 
protease activity [148]. Recent studies have shown that loss of HtrA2 results in 
mitochondrial accumulation of unfolded proteins and oxidative stress that activates a 
mitochondrial stress response resulting in the induction of the transcription factor C/EBP-
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homologous protein (CHOP) and neuronal death, likely involving a mitochondria-ER 
crosstalk [155]. However, the role of HtrA2 within the mitochondria remains unclear and 
some studies have questioned its contribution in PD pathogenesis at least as a component of 
the Parkin/PINK1 pathway [156]. Transgenic mice expressing pathogenic mutants of  α-
synuclein (A53T mice) also show mitochondrial abnormalities linked to neural 
degeneration [157]. Although these mice develop profound adult-onset motor  
abnormalities that progress to paralysis and death, a definitive role of mitochondrial 
dysfunction as a contributing factor in this mouse model needs to be established. The 
possible relationship between increased alpha synuclein levels, mitochondrial defects and 
PD pathology is reinforced by a recent study where accumulation of α-synuclein in the 
mitochondria of human dopaminergic neurons results in reduced complex I activity and 
increased production of ROS, whereas α-synuclein lacking the mitochondrial targeting 
signal fails to associate with mitochondria and induce mitochondrial dysfunction [158]. The 
physiological task of α-synuclein is poorly defined, however, consistent with its ubiquitous 
distribution in brain. However, different studies have described a role for α-synuclein in 
brain lipid metabolism, where its deletion results in an elevation of cholesterol and 
cholesteryl esters [159]. Interestingly, in α-synuclein knockout mice the elevated 
cholesterol levels correlate with increased mitochondrial membrane order and electron 
transport chain impairment [160]. Although mitochondrial GSH levels have not been 
specifically analyzed in this mouse model, it is conceivable that lipid abnormalities, and in 
particular the cholesterol upregulation may result in decreased mitochondrial GSH stores, 
which in turn, may play a role in PD progression as described in AD. To date whether 
cholesterol homeostasis is altered in PD is unknown and will need future studies. 
Altogether, although it seems well established that PD has a mitochondrial component, 
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however, whether dysfunctional mitochondria are the common denominator that leads to 
the different aspects of PD pathogenesis is still an open question. 
3.3. Huntington’s disease (HD) 
HD neuropathology is characterized by the preferential degeneration of striatal medium 
spiny neurons secreting γ-aminobutyric acid (GABAergic neurons), which extends to other 
brain regions as the disease progresses. The abnormal polyglutamine tract expansion within 
a cytosolic protein called huntingtin (htt) has been described as the causative factor for HD 
[161]. Although the pathogenic processes triggered by mutant htt have not yet been fully 
identified, a fundamental facet of htt is the blockade of transcription by interfering the 
activity of transcription factors [162]. In addition to this crucial role, it is becoming 
increasingly clear that alterations in mitochondrial function by htt contribute to the HD 
pathogenesis. Studies with immortalized striatal cells from knock-in HD-mouse models and 
brain mitochondria from transgenic mice expressing full-length mutant htt have 
demonstrated that mutant htt interact directly with mitochondria resulting in impaired 
respiration, loss of membrane potential and Ca2+-handling defects [10, 163] (Fig. 3). 
Mutant htt can also initiate the mitochondrial apoptotic pathway by increasing the levels 
and transcriptional activity of p53 [164] (Fig. 3). Moreover, genetic deletion of p53 
suppresses mitochondrial membrane depolarization and cytotoxicity in HD cells, and 
prevents the neurobehavioral abnormalities of mutant htt transgenic mice. In addition, 
studies in knockout mice have linked deficiencies on PGC-1α, a potent stimulator of 
mitochondrial biogenesis, with HD-like phenotype [165, 166]. Mutant htt has been shown 
to impair PGC-1α activity by blocking the transcription of its gene [167] (Fig. 3). As 
previously mentioned PGC-1α is also a powerful regulator of ROS metabolism, required 
for the induction of many ROS-detoxifying enzymes [62]. Thus, the ability of PGC-1α to 
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increase mitochondrial electron transport activity while stimulating a broad anti-ROS 
program makes this protein a powerful tool for controlling the damage associated with 
defective mitochondrial function seen not only in HD but also in other neurodegenerative 
diseases. PGC-1α is directly deacetylated and activated by sirtuin type1 (SIRT1), a member 
of the sirtuin family of protein deacetylases [168]. SIRT1 is involved in the regulation of 
transcriptional silencing as well as in the deacetylation of both histone and a growing 
number of non-histone substrates, modulating not only the mitochondrial function, via 
PGC-1α activation, but also other critical mechanisms in ageing-related neurodegeneration, 
including removal of protein aggregates (decay-accelerating factor -16, DAF-16), 
regulation of stress responses (FOXO; p53) and inflammatory processes (nuclear factor of 
kappa light polypeptide gene enhancer in B-cells 1, NF-kB; liver X-activated receptor, 
LXR) [169]. Therefore, the manipulation of sirtuin activities, either by SIRT-activating 
compounds such as resveratrol or by metabolic conditioning associated with caloric 
restriction has neuroprotective effects that hold great promise as a potential therapeutic 
strategy for neurodegenerative diseases.  
Finally, in further supporting a role for mitochondria dysfunction in HD, we have observed 
that mitochondrial GSH depletion in caveolin-1 knockout mice due to cholesterol 
accumulation sensitized to 3-nitropropionic acid (3-NP)-induced neuronal death and HD 
pathology (Bosch et al., unpublished data). In line with these observations involving 
mitochondrial dysfunction, it has been recently reported that the targeting of hypoxia 
inducible factor (HIF-1α) and prolyl hydroxylases by chemical inhibitors protect against 3-
NP and MPTP-mediated neuronal death, establishing a link between mitochondrial 
dysfunction and HIF-1α signaling pathway in neurodegeneration [170, 171]. Parallel to the 
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caveat outlined above for PD disease, the relevance of these studies using neurotoxic agents 
as an experimental approach for HD has to be taken cautiously.  
3.4. Amyotrophic lateral sclerosis (ALS) 
ALS is characterized by selective premature degeneration and death of motor neurons, 
which control voluntary actions. Familial ALS-linked mutations in the Cu,Zn-superoxide 
dismutase (SOD1) gene cause motor neuron death in about 3% of ALS cases. Intriguingly, 
mutations in SOD1 associated with ALD phenotype results in a gain-of-function with an 
enhanced free radical-generating capacity compared to wild type enzyme [172, 173]. In 
affected neurons mutated SOD1 (mutSOD) targets mitochondria and forms aggregates 
[174, 175] that lead to structural alterations, such as mitochondrial swelling and 
vacuolization [176, 177]. The presence of cross-linked oligomers of mutSOD1 causes a 
shift in the redox state of these organelles and inhibits complex II and IV of the 
mitochondrial electron transport chain resulting in loss of membrane potential [178, 179] 
(Fig. 3).  
Mice expressing mutations in SOD1 recapitulate the main clinical and pathological features 
of the disease. Mitochondria from these mouse models of human ALS show increased 
vulnerability and impaired Ca2+ homeostasis [180] that precedes the onset of motor 
symptoms [181]. In fact, while the wild-type protein is anti-apoptotic, mutSOD1 seems to 
promote the mitochondrial apoptotic pathway. First, it has been suggested that mutSOD1 
by increasing the levels of oxidized cardiolipin in the brain of mutSOD1 transgenic mice 
may disrupt the association of cytochrome c with the inner mitochondrial membrane, 
thereby priming the apoptotic program [182]. In addition, Bcl-2 can bind to mutSOD1-
containing aggregates in mitochondria contributing to the depletion of this anti-apoptotic 
protein in motor neurons [183]. Moreover, recent data show that the genetic deletion of 
 25 
CypD has robust effects in ALS mice by delaying disease onset and extending survival, 
supporting the participation of MPT in the causal mechanisms of motor neuron 
degeneration [184] (Fig. 3). The mechanisms whereby mutSOD1 contribute to 
mitochondrial dysfunction are still unknown. Since mutSOD1 exhibits a gain-of-function it 
may be conceivable that accelerated superoxide anion scavenging to hydrogen peroxide in 
mitochondria could overwhelm the GSH redox system, particularly if GSH availability in 
mitochondria becomes limited, resulting in potential generation of hydroxyl radical, 
although this remains to be critically established. 
Interestingly, before the activation of apoptotic proteins, motor neurons exhibit 
mitochondrial abnormalities at the innervated neuromuscular junction with high levels of 
mutSOD1 in the presynaptic terminals. Indeed, neuromuscular denervation and 
mitochondrial vacuolization is present in the absence of apoptotic death in mutSOD1 
transgenic mice crossed with Bax knockout mice [185], indicating that mitochondrial 
changes in distal axons may trigger the mechanisms responsible for axonal degeneration 
and denervation. Furthermore, overexpression of mutSOD1 in cell cultures has shown to 
significantly disrupt both anterograde and retrograde mitochondrial transport [186, 187]. 
These trafficking abnormalities along with the observations of mitochondrial fragmentation 
and axonal clustering [188, 189] are highly suggestive that mitochondrial dynamics 
modulated by mutSOD1 may play a critical role in ALS pathogenesis. However, as 
mutSOD1 only account for 3% of ALS cases the mitochondrial role in the pathogenesis of 
most common sporadic form of ALS has to be yet proved. 
4. AUTOPHAGY, MITOCHONDRIAL DYNAMICS AND MITOPHAGY.  
Autophagy is the generic term for pathways that transport cytosolic contents to lysosomes 
for its degradation, thought to play a critical housekeeping role to nourish cells and prevent 
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accumulation damaged organelles, including mitochondria. First, we will briefly describe 
this process to focus then on mitophagy and relation to neurodegeneration. 
Two main types of autophagy has been described (macroautophagy and chaperone-
mediated autophagy) that differ with respect to their physiological functions and the mode 
of cargo delivery to lysosomes. In brief, macroautophagy is a bulk degradation pathway 
capable of getting ride of large protein complexes or organelles and involves the formation 
of double-membrane vesicles (autophagosomes or autophagic vacuoles) which fuse with 
lysosomes (autolysosomes or autophagolysosomes) [190]. This is a highly regulated 
process orchestrated by a family of autophagy-related (Atg) proteins and controlled by the 
mammalian target of rapamycin (mTOR) kinase pathway [190]. By contrast, chaperone-
mediated autophagy (CMA) is selective for specific cytosolic proteins that contain a 
pentapeptide Lys-Phe-Glu-Arg-Gln (KFERQ)-like motif, which is recognized by the 70 
kDa heat shock cognate protein (Hsc70) transferring the protein to the lysosomal 
membrane where, through binding to the receptor lysosome-associated membrane protein 
type 2a (lamp2a), is then translocated into the lysosomal lumen [191].   
Autophagy has a fundamental constitutive function in maintaining cellular homeostasis by 
performing a constant turnover of cellular components. This basal clearing mechanism is 
exceptionally efficient in postmitotic cells like neurons with extended life span. 
Interestingly, neuron-specific ablation of autophagy-related genes in mice causes 
ubiquitinated protein aggregates, inclusion bodies and progressive neurodegeneration [192, 
193]. The requirement for autophagy is even more evident under cellular stress conditions. 
Autophagy is upregulated as a catabolic mechanism to provide metabolites for ATP 
generation and biosynthesis in situations of nutrient and growth factor deprivation but also 
as a clearing system that protects cells from cumulative proteins aggregates and oxidatively 
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damaged organelles, such as mitochondria. Therefore, an inadequate or defective 
autophagy may determine cell fate in response to stress conditions and have major 
consequences in several diseases including neurodegenerative disorders. In this regard, 
accumulation of autophagic vacuoles (AV) and mitochondrial autophagy (mitophagy) has 
been reported in several neurodegenerative diseases including AD [194, 195], PD [196, 
197] and HD [198, 199]. Although the role of autophagy in brain neurodegeneration is not 
fully deciphered, the emerging view is that the process is initially induced as a 
neuroprotective response in stressed neurons but is subsequently impaired by several 
disease-related factors. For example, it has been described that autophagosome-like 
structures accumulate in dystrophic neurites of AD patients and model mice due to 
defective maturation of autophagosomes to lysosomes [200]. The immature 
autophagosomes are enriched in APP and become active sites of Aβ synthesis [201]. 
Further support for the correlation between autophagy and Aβ metabolism is shown in APP 
transgenic mice with a genetic reduction in the expression of the autophagic key regulator 
Beclin-1 that display increased Aβ accumulation and profound neuronal abnormalities 
[202]. Autophagy-lysosomal dysfunction has been also described in NPC-1 knockout mice 
indicating that disturbances in cholesterol metabolism might play a regulatory role [203, 
204]. Recent studies show that mutant α-synuclein can block CMA, which in turn, leads to 
lysosomal dysfunction [205, 206]. Dysregulation of this pathway impairs the activity of 
myocyte enhancer factor 2D (MEF2D), a transcription factor required for neuronal survival 
[207]. Additionally, aggregates of mutant huntingtin have been reported to recruit Beclin-1, 
and therefore, inhibiting the induction of autophagy [208]. Similarly, dynein mutations 
cause aggregates clearance defects in HD animal models indicating that autophagy 
dysfunction may also arise from impaired vesicle transport [209].  
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Dysfunctional mitochondria have been previously proposed to activate mitophagy [210, 
211]. Interestingly, recent data from Narendra et al. have linked Parkin to the regulation of 
mitochondrial elimination; Parkin is selectively recruited to mitochondria with low 
membrane potential and subsequently promotes their autophagy [197, 212]. Therefore, the 
loss-of-function of Parkin, implicates a failure to eliminate dysfunctional mitochondria in 
the pathogenesis of Parkinson's disease. Mitophagic insufficiency may culminate in a 
progressive accumulation of ROS-generating mitochondria exacerbating the cellular stress 
[213], however, whether this is the case in neurodegenerative diseases remains unknown. A 
detailed understanding of the regulatory relationship between mitochondria and autophagy 
would help to decipher their beneficial or detrimental effects on neurodegeneration. 
Mitochondria are dynamic organelles that actively divide, fuse with one another and 
interact with other cellular organelles. Fission and fusion processes are important in 
maintaining the integrity of mitochondria, in mitochondrial redistribution and turnover, as 
well as in segregation, stabilization, and protection of mtDNA [214, 215]. In neurons, the 
mitochondrial fission/fusion machinery is intimately involved in the formation of synapses 
and dendritic spines. Prevention of mitochondrial fission leads to a loss of mitochondrial 
network from dendritic spines and a reduction of synapse formation [216]. A group of 
conserved large dynamin-related GTPases is responsible for the balance between 
mitochondrial fission and fusion. Dynamin-related protein (Drp1) is a key mediator of 
mitochondrial fission [217]. Mitochondrial fission (Fis1) in yeast and its mammalian 
homologue hFis1 are also involved in mitochondrial fission, likely playing a role in Drp1 
recruitment to the mitochondria. GTP hydrolysis is thought to cause a conformational 
change in Drp1 that drives the mitochondrial outer membrane fission event [218, 219]. In 
contrast to fission, mitochondrial fusion requires both outer and inner membrane 
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components. Mitofusins 1, 2 (Mfn 1, 2) facilitate outer membrane fusion in mammals, 
likely through trans interactions that promote membrane curvature and fusion, whereas, the 
GTPase optic atrophy 1 (OPA1) is the main mediator of inner membrane fusion [220, 221]. 
Recent data suggest that mitochondrial dynamics may have a role in the management of 
oxidative damaged organelles. Mitochondrial fusion could complement an injured unit and 
possibly recover its activity, thereby maintaining the metabolic efficiency [222]. 
Mitochondrial fission could also have a protective role by the segregation of damaged and 
inactive mitochondria that facilitates autophagic clearance [214, 223]. In particular, studies 
from Twing et al. reveal that the fission events often generate a subpopulation of non-
fusing and autophagocytosed mitochondria with reduced ∆Ψm and decreased levels of the 
fusion protein OPA1 [223]. Conversely, either inhibition of the fission machinery or 
overexpression of OPA1 decrease mitochondrial autophagy and result in accumulation of 
oxidized mitochondrial proteins and impaired respiration [223].  
The clinical relevance of a finely tuned balance between fission and fusion processes is 
underscored by the fact that the pathogenesis of certain hereditary neurodegenerative 
disorders such as autosomal dominant optic atrophy (ADOA) and Charcot-Marie-Tooth 
neuropathy type 2A (CMT2A) can be linked to mutations in genes encoding mediators of 
mitochondrial fusion [224, 225]. The association of neurodegeneration with impaired 
mitochondrial dynamics is further supported by growing evidence suggesting that mutant 
proteins which cause more common chronic neurodegenerative diseases, may interact with 
fission/ fusion GTPases resulting in increased mitochondrial fragmentation. Thus, Aβ 
overproduction has been shown to cause abnormal mitochondrial dynamics via differential 
modulation of mitochondrial fission/fusion proteins [226]. Nitric oxide produced in 
response to Aβ, has been proposed to trigger mitochondrial fission, synaptic loss, and 
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neuronal damage, in part via S-nitrosylation of Drp1 [227]. In addition, studies from several 
groups either in Drosophila melanogaster and mammalian cells suggest an emerging 
consensual view that PD-related PINK1/Parkin pathway regulates mitochondrial fission 
and fusion machinery [228, 229]. PINK1 deficiency leads to fragmented mitochondrial 
cristae, hypersensitivity to oxidative stress, and neuronal degeneration and is rescued by 
overexpression of parkin and fission factors Drp1 or Fis1 [146, 230-232]. Interestingly, a 
recent study indicates that a coordinated regulation of mitochondrial dynamics and 
mitophagy triggered by mitochondrial oxidant generation limits cell death associated with 
loss of PINK1 function [233]. In this work Parkin overexpression enhances the protective 
mitophagic response, whereas RNA-interference knockdown of autophagy proteins 
decreases mitochondrial fragmentation, underscoring the inter-relationship between both 
processes. 
5. CONCLUDING REMARKS 
Evidence strongly supports the role of mitochondrial oxidative stress as a common 
denominator in the pathogenesis of ageing-related neurodegenerative diseases. Data from 
genetically-modified mice that express the disease-causing mutations have provided a 
valuable tool to demonstrate that oxidative damage, mitochondrial dysfunction and 
defective degradation of protein aggregates and impaired organelles are three interrelated 
molecular processes responsible for cell death in neurodegeneration. Moreover, the 
discovery that most of the disease-specific proteins interact with mitochondria has 
unraveled new potential therapeutic targets; still, an important point to take into 
consideration is that genetic forms of the neurodegenerative diseases are only a small 
percentage of early-onset cases, therefore, the relevant role of mitochondria observed in 
mouse models must be also proved for sporadic late-onset cases. Beside that the onset of 
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oxidative stress and functionally affected mitochondria are features typically associated 
with brain ageing, further research is required first to elucidate whether mitochondrial 
dysfunction plays only a contributory role or is an early seminal event in non-inherited 
forms of neurodegenerative diseases and second and, most important, to design effective 
strategies to cope with mitochondrial oxidative stress. To date antioxidant therapies have 
been modestly successful in clinical trials, with best outcomes reflected in just delaying the 
progression of neurodegeneration. Indeed, increasing the antioxidant cellular content may 
not necessarily result in mitochondrial protection. We have recently shown that elevated 
cholesterol in AD may specifically deplete the mitochondrial pool of GSH by impairing its 
transport into mitochondria, suggesting that efforts should be directed to bypass the 
transport blockade imposed by cholesterol deposition. These observations on the role of 
mitochondrial cholesterol in the susceptibility to AD imply that not all GSH precursors 
would be expected to be of benefit in exerting disease-modifying effects in AD progression, 
although they may be able to boost the cytosolic GSH pool. Further implications from these 
findings indicate that only permeable GSH prodrugs able to penetrate mitochondria would 
result in effective replenishment of this critical pool of GSH, which may protect 
mitochondria from Aβ-mediated neurotoxicity.   
The generation and use of genetically modified mice as experimental models of 
neurodegeneration have been extremely valuable in increasing our understanding of the 
basics of neurodegenerative diseases and in the identification of potential therapeutic 
targets for the future. However, they may also highlight the disparity between these models 
and human neurodegeneration, as recently illustrated for the case of memantine showing a 
significant effectiveness in transgenic AD mice but very modestly so in humans.  In 
addition to our expectation to discover novel therapies for these devastating diseases, the 
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available mouse models may be very helpful to test new or current therapy as disease or 
hypothesis-modifying drugs. With respect to mitochondrial function and oxidative stress, it 
is to be expected that therapeutic agents having the ability to target mitochondria may 
exhibit hypothesis or disease-modifying effects. Moreover, although the expectation of the 
translational application of the experimental therapeutics identified in mouse models to 
human disease has not been fulfilled, this could well reflect our limitation in the 
understanding the complex interactions/mechanisms of oxidant and antioxidant actions in 
mitochondria to design effective therapies. For instance, a broad approach might include 
the activation of transcription factors like PGC-1α, a potent stimulator of mitochondrial 
biogenesis but also required for the induction of many ROS-detoxifying enzymes, in 
combination with the activation of mitophagy processes that would eliminate damaged 
mitochondria and prevent the accumulation of ROS-generating organelles. Clearly, a 
greater understanding of how mitochondrial dynamics are involved with the pathogenesis 
of neurodegenerative diseases and the significant neuroprotective properties of mitophagy 
activation could be pivotal to develop new therapeutic interventions. 
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FIGURE LEGENDS 
 
Fig. (1). Mitochondrial ROS generation. The main superoxide (O2.-)-producing sites in 
mitochondria are the redox centers in complex I and complex III of the electron transport 
chain (ETC). O2.- formation at complex I occurs primarily on the matrix side of the inner 
membrane (IM) through both forward electron transfer, involving electrons originating 
from NADH, and reverse electron transfer, with electrons derived from succinate, the 
substrate of complex II. The formation of ROS by complex III appears at both sides of the 
IM and is attributed to the access of O2 to semiquinone radical intermediate (QH.) formed 
at the Qo site during redox cycling of coenzyme Q (Q-cycle). Mitochondrial flavoenzymes 
like monoamine oxidase (MAO) in the mitochondrial outer membrane (OM), and the 
dihydrolipoyl dehydrogenase within the α-ketoglutarate dehydrogenase complex 
(KGDHC), localized in the matrix side of the IM, are also sources of ROS. Additionally, 
Ca2+ overload may favor ROS generation by several mechanisms: 1. Stimulation of the 
TCA cycle that will enhance electron flow through the ETC, 2. induction of nitric oxide 
synthase (NOS) and subsequent nitric oxide (NO) generation that would inhibit complex I 
and IV, and 3. dissociation of cytochrome c (cytC) and its release via the mitochondrial 
permeability transition (MPT) pore. 
Fig. (2). Mitochondrial control of oxidative stress. Anion superoxide (O2.-)  has a very 
short half-life being rapidly dismutated into H2O2 and O2 by manganese superoxide 
dismutase (Mn-SOD) in the mitochondrial matrix. Excessive O2.- and hydrogen peroxide 
(H2O2) levels can result in generation of the highly reactive hydroxyl radicals (.OH) via 
Haber-Weiss and Fenton reactions. A network of antioxidant enzymatic reactions takes 
place in mitochondria to eliminate ROS and repair oxidative modification in proteins, 
membrane lipids and DNA. Glutathione peroxidases (Gpx)  catalyze the reduction of H2O2 
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and various hydroperoxides, with glutathione (GSH) as the electron donor and the 
subsequent conversion of GSH disulfide (GSSG) back into GSH by the NADPH-dependent 
glutathione reductase (GR). Protein disulfides can be also reduced by the action of 
mitochondrial thioredoxins (Trx2) and glutaredoxins (Grx2). In addition, mitochondrial 
Peroxiredoxins (PrxIII) use the peroxidatic cysteine (reactive center) to reduce 
hydroperoxides in two-steps; first, the Cys residue of each subunit of the Prx homodimer is 
oxidized to Cys-SOH, which then reacts with neighboring Cys-SH of the other subunit to 
form an intermolecular disulfide. The disulfide is reduced specifically by Trx2, which is 
subsequently regenerated by thioredoxin reductase 2 (TrxR2) at the expense of NADPH. 
Fig. (3). Mitochondria are a critical target in ageing-related neurodegenerative 
diseases. Scheme depicting different interactions of disease-specific proteins with 
mitochondria that lead to ROS, mitochondrial failure and cell death. Most of mutated 
proteins target different complexes of the electron transport chain (ETC) resulting in ROS 
generation. Specifically, amyloid-β (Aβ) also induces oxidative stress by interacting with 
the amyloid-binding alcohol dehydrogenase (ABAD) and promotes mitochondrial 
permeability transition (MPT) by binding to cyclophilin D (CypD). In Parkinson’s disease, 
the alteration of the parkin/PINK1 inter-regulatory pathway impairs mitochondrial 
dynamics and function. Mutated PINK1 might also affect the protease activity of HtrA2 
that, in turn, would activate a mitochondrial stress response with the induction of the 
transcription factor CHOP. In addition, PINK1 can increase the mitochondrial Ca2+ levels 
and promote MPT, similarly as described for the pathogenic mutant huntingtin (htt) and 
Cu,Zn-superoxide dismutase (SOD1). Both, htt and SOD1 enhance the mitochondrial 
apoptotic pathway by increasing p53 levels and reducing the anti-apoptotic Bcl-2 levels, 
respectively. Decreased mitochondrial antioxidant capacity, i.e. as a result of an increase in 
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mitochondrial membrane cholesterol (CHOL) that affects the mitochondrial GSH transport 
or an impairment of the transcriptional activity of PGC-1α, would exacerbate the oxidative 
stress mediated by pathogenic mutant proteins. Glutathione (GSH), GSH peroxidase (Gpx), 
α-ketoglutarate dehydrogenase complex (KGDHC), Mn-dependent superoxide dismutase 
(MnSOD).  
 
 
